Recent News

• 09.08.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.02.2025 - Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
• 09.02.2025 - Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
• 08.14.2025 - Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update
• 08.14.2025 - Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update
• 07.09.2025 - Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026
• 07.09.2025 - Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026
• 06.10.2025 - Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension
• 06.10.2025 - Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension

Recent Filings

• 08.14.2025 - EX-99.1 EX-99.1
• 08.14.2025 - 8-K Current report
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.09.2025 - 8-K Current report
• 07.09.2025 - EX-99.1 EX-99.1
• 06.16.2025 - 8-K Current report
• 06.16.2025 - EX-99.1 EX-99.1
• 06.11.2025 - 4 Statement of changes in beneficial ownership of securities